Investigational drug · Phase 2
CFI-402257
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Solid Tumor, Breast Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: May 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "CFI-402257"
First trial start
2022
May 27, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CFI-402257", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumor
- Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "CFI-402257" as an intervention, largest first.
Canadian Cancer Trials GroupResearch network
NCT05601440 · 484 participants (planned) · Start Jun 13, 2023 · Primary completion Dec 31, 2027
Drug: RP-6306; Gemcitabine and 6 more · For: Breast Cancer
Sites: Calgary, Canada; Kelowna, Canada; Vancouver, Canada · 10 sites in all
University Health Network, TorontoAcademic, hospital or other
NCT02792465 · 52 participants (planned) · Start Nov 11, 2016 · Primary completion Jun 12, 2025
Drug: CFI-402257; Fulvestrant · For: Advanced Solid Cancers; Breast Cancer
Sites: Vancouver, Canada; Ottawa, Canada; Toronto, Canada
- CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast CancerActive, not recruiting
Treadwell Therapeutics, IncIndustry
NCT05251714 · 44 participants (planned) · Start May 27, 2022 · Primary completion Aug 2026
Drug: CFI-402257; Fulvestrant · For: Advanced Solid Tumor; Breast Cancer
Sites: Columbus, Ohio; San Antonio, Texas; West Valley City, Utah · 4 sites in all
- CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast CancerActive, not recruiting
Canadian Cancer Trials GroupResearch network
NCT03568422 · 37 participants · Start Feb 5, 2019 · Primary completion Nov 21, 2022
Drug: CFI-402257; Paclitaxel · For: Breast Cancer
Sites: Vancouver, Canada; Kingston, Canada; Ottawa, Canada · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- cGAS-STING Signalling in the tumour microenvironment: Implications for immune surveillance and therapeutic strategies.
Al-Adayleh TYM, Ahmad W, Rahiman SSF, et al. · Int Immunopharmacol 2026
- Genome-Wide CRISPR Screens Identify ABCG2-Mediated Drug Resistance to the Threonine Tyrosine Kinase (TTK) Inhibitor CFI-402257 in Breast Cancer.
Thu KL, Jafari S, Silvester J, et al. · Int J Mol Sci 2026
- PELI1 in human cancers: a pan-cancer exploration of its molecular function, clinical significance, and immunomodulatory roles.
Xu Y, Zhou J, Chen X, et al. · Front Immunol 2025
- Targeting monopolar spindle kinase I (Mps1 or TTK) induces radiosensitization in syngeneic models of triple negative breast cancer (TNBC) and potentiates type I interferon (T1IFN) signaling.
Jungles KM, Bishop CR, Wilson CM, et al. · Neoplasia 2025
- Targeting TTK Inhibits Tumorigenesis of T-Cell Lymphoma Through Dephosphorylating p38α and Activating AMPK/mTOR Pathway.
Liu B, Lu T, Ding M, et al. · Adv Sci (Weinh) 2025
- TTK Inhibition Alleviates Postinjury Neointimal Formation and Atherosclerosis.
Wu JH, Liu YX, Zong JB, et al. · Adv Sci (Weinh) 2025
Also in development for Advanced Solid Tumor
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.